다발성 경화증(MS) 참가자의 신경필라멘트 경쇄(NfL) 수준 및 참가자 만족도에 대한 오크렐리주맙 치료의 효과를 조사하기 위한 연구 (SurfSubQ)
다발성 경화증 환자의 피하 오크렐리주맙 투여 후 신경필라멘트 경쇄 수준 및 환자 만족도를 조사하기 위한 전향적 종단적 다기관 관찰 연구
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Reference Study ID Number: ML45551 https://forpatients.roche.com/ No attachments to email below
- 전화번호: 888-662-6728 (U.S. Only)
- 이메일: global-roche-genentech-trials@gene.com
연구 연락처 백업
- 이름: Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry
연구 장소
-
-
-
Aachen, 독일, 52074
- 모병
- Uniklinik RWTH Aachen
-
Amberg, 독일, 92224
- 모병
- Gesundheitszentrum St. Marien GmbH
-
Arnsdorf, 독일, 01477
- 모병
- Sächsisches Krankenhaus Arnsdorf
-
Aschaffenburg, 독일, 63739
- 모병
- Neuropraxis im Stadtpalais Dres. Ulzheimer/Herröder/Wessig GbR
-
Bad Soden, 독일, 65812
- 모병
- Neurologie Bad Soden
-
Bamberg, 독일, 96052
- 모병
- Neurologische Praxis - Kallmann Neurologie - mszb
-
Berg, 독일, 82335
- 빼는
- Marianne-Strauß-klinik
-
Berlin, 독일, 13347
- 모병
- Jüdisches Krankenhaus Berlin
-
Berlin, 독일, 12099
- 모병
- NEUROZENTRUM tempelhof.berlin
-
Berlin, 독일, 10713
- 모병
- Neurologisches Facharztzentrum Berlin am Sankt Gertrauden-Krankenhaus
-
Berlin, 독일, 12099
- 모병
- Praxis Dr. Said Masri
-
Berlin, 독일, 14169
- 모병
- NeuroZentrum Zehlendorf Dr. Ringel und Dr. Scherer
-
Berlin, 독일, 14195
- 모병
- Neurologisches Zentrum für Bewegungsstörungen und Diagnostik
-
Bochum, 독일, 44791
- 모병
- St. Josef-Hospital
-
Bogen, 독일, 94327
- 모병
- Dres. Lippert/Kausch
-
Buchholz, 독일, 21244
- 빼는
- Krankenhaus Buchholz Abt. Neurologie
-
Celle, 독일, 29223
- 모병
- Neuropraxis Celle: Praxis für Neurologie & Psychatrie
-
Celle, 독일, 29223
- 모병
- Allgemeines Krankenhaus Celle / Klinik für Neurologie
-
Chemnitz, 독일, 09117
- 모집하지 않고 적극적으로
- Praxisgemeinschaft Dres. Sylke Domke und Vasil Gjaurov
-
Cologne, 독일, 50935
- 모병
- NeuroMed Campus Neurologische Gemeinschaftspraxis am St. Elisabeth Krankenhaus
-
Dortmund, 독일, 44137
- 빼는
- Gemeinschaftspraxis Dr. med. Josef Leclaire und Dr. med. Thomas Rotermund
-
Düsseldorf, 독일, 40225
- 모병
- Universitätsklinikum Düsseldorf
-
Düsseldorf, 독일, 40211
- 모병
- Gemeinschaftspraxis für Neurologie
-
Düsseldorf, 독일, 40625
- 빼는
- Nervenarztpraxis Gerresheim
-
Eltville, 독일, 65343
- 모병
- Gemeinschaftspraxis für Neurologie und Psychiatrie, Psychotherapie
-
Erbach/Odenwald, 독일, 64711
- 모병
- NeuroCentrum Odenwald
-
Erlangen, 독일, 91054
- 모병
- Universitätsklinikum Erlangen, Neurologische Klinik
-
Essen, 독일, 45138
- 모병
- Zentrum für ambulante Neurologie / Praxis Knorn Landefeld Friedrich
-
Essen, 독일, 45257
- 모병
- Praxis Nervenstark
-
Forchheim, 독일, 91301
- 완전한
- Praxis für Neurologie, Nervenheilkunde & Neurochirurgie
-
Frankfurt, 독일, 65929
- 모병
- Varisano Klinikum Frankfurt Höchst GmbH
-
Frankfurt, 독일, 60528
- 모병
- Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie
-
Freiburg im Breisgau, 독일, 79106
- 모병
- Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
-
Füssen, 독일, 87629
- 모병
- Praxis im Bahnhof
-
Giessen, 독일, 35392
- 모병
- Universitätsklinikum Gießen und Marburg GmbH
-
Gladenbach, 독일, 35075
- 모병
- Neurologie & Psychiatrie Gladenbach - MS-Zentrum
-
Günzburg, 독일, 89312
- 모병
- MVZ Bezirkskliniken Schwaben, Standort Günzburg
-
Halle, 독일, 06120
- 모병
- Krankenhaus Martha-Maria Halle-Doelau
-
Hamburg, 독일, 20249
- 모병
- Neurologische Praxis Eppendorf
-
Hamburg, 독일, 20246
- 모병
- Universiätsklinikum Hamburg-Eppendorf
-
Hanover, 독일, 30171
- 모병
- Neurologische Praxis
-
Hennigsdorf, 독일, 16761
- 모병
- Oberhavel Kliniken GmbH, Klinik Hennigsdorf, Neurologie
-
Herford, 독일, 32052
- 모병
- Praxis Dr. Hospely
-
Hettingen, 독일, 72513
- 모병
- Haus- und Facharztzentrum Laucherttal / Alb
-
Ibbenbueren, 독일, 49477
- 모병
- Klinikum Ibbenbüren gmbH
-
Isselburg, 독일, 46419
- 모병
- Augustahospital Anholt;Neurologie
-
Jena, 독일, 07747
- 모병
- Universitätsklinikum Jena, Klinik für Neurologie
-
Kiel, 독일, 24105
- 모병
- Uniklinik Schleswig-Holstein
-
Leipzig, 독일, 04315
- 모병
- Neurologische Praxis Dr. Ehrlich
-
Leipzig, 독일, 04299
- 모병
- Arztpraxis Dr. med. Torsten Sühnel
-
Lübeck, 독일, 23538
- 모병
- Universitätsklinik Schleswig Holstein, Campus Lübeck
-
Magdeburg, 독일, 39120
- 모병
- Universitätsklinikum Magdeburg
-
Magdeburg, 독일, 39104
- 모병
- Neurologie im Ulrichshaus Magdeburg
-
Mannheim, 독일, 68167
- 모병
- Universitätsklinikum Mannheim
-
Mannheim, 독일, 68163
- 모병
- Neuroplus Dres. Lennart Thilmann/ Patrick Thilmann
-
Marburg, 독일, 35043
- 모병
- Universitätsklinikum Giessen und Marburg
-
Meerbusch, 독일, 40667
- 모병
- Praxis Dr. Leussink
-
Minden, 독일, 32423
- 모병
- Neurologie am Preußenmuseum
-
München, 독일, 81675
- 모병
- Praxis für Neurologie und Psychiatrie am Prinzregentenplatz
-
München, 독일, 80939
- 모병
- Neurologie München Nord
-
München, 독일, 81675
- 모병
- Klinikum rechts der Isar der TU München
-
Münster, 독일, 48149
- 모병
- Universitätsklinikum Münster
-
Münster, 독일, 48165
- 모병
- Herz-Jesu-Krankenhaus Hiltrup GmbH
-
Neu-Ulm, 독일, 89231
- 모병
- Neurologisch-psychiatrische Praxis im A4
-
Neuburg am Inn, 독일, 86633
- 모병
- Praxis Dr. med. Bergmann
-
Neuruppin, 독일, 16816
- 모병
- Ruppiner Kliniken, Hochschulklinikum der Medizinischen Hochschule Brandenburg, Klinik für Neurologie
-
Nuremberg, 독일, 90451
- 모병
- Neurologie Nürnberg-Eibach
-
Nuremberg, 독일, 90419
- 모병
- Gemeinschaftspraxis Uhlig und Windsheimer
-
Osnabrück, 독일, 49074
- 빼는
- Neurologie an der Hase
-
Pforzheim, 독일, 75172
- 모병
- Facharztpraxis für Neurologie und Psychiatrie Dres Mattes/Stockert
-
Quakenbrück, 독일, 49610
- 모병
- Neurologisches Studienzentrum Artland
-
Regensburg, 독일, 93059
- 모병
- Gemeinschaftspraxis für Neurologie
-
Remscheid, 독일, 42853
- 모병
- Gemeinschaftspraxis Dr. Stienker-Fisse & Dr. Fisse
-
Rülzheim, 독일, 76761
- 모병
- ZNS Südpfalz
-
Schwetzingen, 독일, 68723
- 모병
- Neurologische Praxis Dr. Wagner
-
Siegen, 독일, 57076
- 모병
- Praxis für Neurologie und Psychiatrie
-
Siegen, 독일, 57072
- 모병
- Gemeinschaftspraxis für Neurologie, Psychiatrie und Psychotherapie
-
Singen, 독일, 78224
- 모병
- EMSA - Zentrum für Neurologie?/?Psychiatrie?/?Neuroradiologie
-
Sinsheim, 독일, 74889
- 모병
- Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim
-
Steglitz, 독일, 12163
- 모병
- Gemeinschaftspraxis Dr. Wolfram von Pannwitz, MBA & Dr. med. Marie Perle Brinckmann
-
Stuttgart, 독일, 70174
- 모병
- Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie
-
Stuttgart, 독일, 70176
- 모병
- Neuropraxis Sotiriadis
-
Stuttgart, 독일, 70178
- 모병
- Neurozentrum Stuttgart Mitte Sophienstraße
-
Sundern, 독일, 59846
- 모병
- Sauerlandklinik Hachen
-
Tübingen, 독일, 72076
- 모병
- Universitätsklinikum Tübingen, Zentrum für Neurologie
-
Ulm, 독일, 89078
- 모병
- Nervenfachaerztliche Gemeinschaftspraxis Ulm
-
Unterhaching, 독일, 82008
- 모병
- Neuropraxis München Süd
-
Weil der Stadt, 독일, 71263
- 모병
- Praxis für Neurologie, Psychiatrie und Epileptologie
-
Wolfratshausen, 독일, 82515
- 모병
- Praxis Dr. Michaela Krause
-
Zwickau, 독일, 08060
- 모병
- Heinrich-Braun-Krankenhaus Städtisches Klinikum
-
Öhringen, 독일, 74613
- 모병
- Dres. Beckmann / Schlüter
-
-
-
-
-
Bern, 스위스, 3010
- 모병
- Inselspital-Universitaetsspital Bern
-
Zurich, 스위스, 8001
- 모병
- Bellevue Medical Grop AG
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Participants with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), diagnosed according to McDonald criteria of 2017 or revised McDonald criteria 2024, and treated with ocrelizumab SC for the first time during routine clinical practice will be observed in this study.
설명
Inclusion Criteria:
- Diagnosis of MS
- RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024
- First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab
Exclusion Criteria:
- Participation in interventional studies investigating DMTs for MS
- Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
- Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
- Severe psychiatric disability
- Pregnant women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Ocrelizumab
Participants who are receiving ocrelizumab, SC injection, for the first time as part of their routine MS therapy at physician's discretion in accordance with local clinical practice and/or labeling will be observed for treatment satisfaction with SC injection for up to 12 months. |
Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC
기간: Month 12
|
TASQ-SC is a 12-item, participant-reported questionnaire measuring the impact of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each of the domain/scale scores is scored on a scale of 1-100, where higher scores indicate higher overall satisfaction with the therapy. |
Month 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
혈청 내 NfL 단백질 수준의 농도
기간: 기준선, 6개월, 12개월
|
기준선, 6개월, 12개월
|
|
|
의사 설문조사에 의해 평가된 Ocrelizumab SC에 대한 만족도 수준별 참가자 수
기간: 기준선, 6개월, 12개월
|
기준선, 6개월, 12개월
|
|
|
연간 재발률
기간: 12개월
|
12개월
|
|
|
재발 활동과 무관하게 진행되는 참가자의 비율(PIRA)
기간: 12개월까지
|
12개월까지
|
|
|
심각하지 않은 부작용(nsAE), 심각한 부작용(SAE) 및 특별 관심 대상의 부작용(AESI)이 발생한 참가자 수
기간: 12개월까지
|
12개월까지
|
|
|
Change From Baseline in NfL Protein Levels in Serum
기간: Baseline, Month 6, Month 12
|
Baseline, Month 6, Month 12
|
|
|
Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After the First Injection and After 6 Months Assessed Using TASQ-SC
기간: Baseline, Month 6
|
TASQ-SC is a 12-item, participant-reported questionnaire measuring the impact of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each of the domain/scale scores is scored on a scale of 1-100, where higher scores indicate higher overall satisfaction with the therapy. |
Baseline, Month 6
|
|
Correlation Between NfL Protein Levels in Serum With MS Relapse
기간: Up to Month 12
|
The changes in levels of NfL protein levels in serum and its correlation with MS relapse will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Expanded Disability Status Scale (EDSS)
기간: Up to Month 12
|
The changes in levels of NfL protein levels in serum and its correlation with EDSS will be analyzed using Pearson or Spearman correlation coefficients. EDSS is a scale for assessing neurologic impairment in MS. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Previous MS Disease Modifying Therapy (DMT)
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with DMT will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Serum Creatinine
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with serum creatinine will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Co-morbidities
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with co-morbidities will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Age
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with age will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Body Mass Index [BMI]
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with BMI will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Magnetic Resonance Imaging (MRI) Lesion Count
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with MRI lesion count will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Glial Fibrillary Acidic Protein (GFAP) Levels
기간: Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with GFAP levels will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With No Evidence of Disease Activity-3 (NEDA-3)
기간: Up to Month 12
|
NEDA-3 is defined by no confirmed MS relapse, no new or enlarging T2 lesions, no Gadolinium-positive T1 lesions, and no six-month confirmed disability worsening. The changes in levels of NfL protein in serum and its correlation with NEDA-3 will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Change From Baseline in Participant Satisfaction With Ocrelizumab SC Assessed Using Treatment Satisfaction Questionnaire for Medication (TSQM) 1.4
기간: Baseline, Month 6, Month 12
|
TSQM version 1.4 is a 14-item questionnaire used to measure level of satisfaction or dissatisfaction with the medication on 4 domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Each of the domain is scored on likert-type scales of 5 or 7 points ranging from 1 (least satisfied) to 5 or 7 (most satisfied). Item scores are summarized to give four domain scores, which are in turn transformed to a scale of 0-100. Higher scores indicate higher overall satisfaction with the therapy. |
Baseline, Month 6, Month 12
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Clinical Trials, Hoffmann-La Roche
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ML45551
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .